Sanara MedTech, Inc. (SMTI)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sanara MedTech, Inc. (“Sanara” or “the Company”) (NASDAQ: SMTI). Investors who purchased Sanara securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sanara has violated federal securities laws.
Investigation Details
On November 11, 2025, after market hours, Sanara announced that it would be “discontinuing operations of [its Tissue Health Plus (“THP”) program] to improve its operating efficiency and reallocate resources to its core surgical business.” The following day, Sanara released its third quarter 2025 financial results, reporting that its “net loss from discontinued operations . . . was $31.2 million,” which “includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP.” Following this news, Sanara’s stock dropped.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Sanara securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]